Nurix Therapeutics, Inc. (NRIX) Reports Q4 Loss, Misses Revenue Estimates
Nurix TherapeuticsNurix Therapeutics(US:NRIX) ZACKS·2026-01-29 07:35

Nurix Therapeutics, Inc. (NRIX) came out with a quarterly loss of 0.82pershareversustheZacksConsensusEstimateofalossof0.82 per share versus the Zacks Consensus Estimate of a loss of 0.84. This compares to a loss of 0.75pershareayearago.Thesefiguresareadjustedfornon−recurringitems.Thisquarterlyreportrepresentsanearningssurpriseof+2.880.75 per share a year ago. These figures are adjusted for non-recurring items.This quarterly report represents an earnings surprise of +2.88%. A quarter ago, it was expected that this company would post a loss of 0.84 per share when it actually produced a loss of $1.03, delivering a surprise of -22.62%.Over the last four quarters, the company ...